Volume 88(1) - 2015

Journal of Biological Research

Bollettino della Società Italiana di Biologia Sperimentale



86th SIBS National Congress

Palermo, Italy, 24-25 October 2013

Botanical Garden, Lanza Hall

ibr

www.jbiolres.org





Synthesis and structure-activity relationship studies of new 3-methyl-5-(5-propyl-1*H*-1-R'-3- pyrazolyl)-1*H*-1-R-4-nitrosopyrazoles as antimicotic agents

S. Aiello, 1 L.C. López-Cara, 2 F. Venturella, 3 A. Licata 4

¹Physiology and Pharmacology Unit, Department of Legal, Social and Sports Sciences, University of Palermo, Italy; ²Department of Pharmaceutical and Organic Chemistry, University of Granada, Spain; ³Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo; ⁴Gastroenterology Unit, Department of Internal and Specialized Medicine, University of Palermo, Italy

Many ubiquitous yeast are primarily pathogens for immunocompromised patients, individuals with AIDS and organ transplanted are at high risk of cryptococcosis and candidiasis. In this setting, fungal infections are particularly difficult to treat because antifungal therapy usually does not eradicate the infection and require lifelong treatment with antifungal drugs. Consequently, the need for novel antifungal agents for opportunistic infections is apparent in light of significant problems associated with current drugs and makes the development of new drug entities all more urgent.

We have reported that some 3-(3-alkyl-4-nitroso-1*H*-5-pyrazolyl)-5-R-isoxazoles¹ and the isomeric 5-(1-alkyl-4-nitroso-1*H*-3-pyrazolyl)-3-R-isoxazoles² showed *in vitro* potent antifungal activity at non cytotoxic concentrations. This antifungal activity was correlated to: i) the interaction of the isoxazolic nitrogen with the alkyl group bound to the pyrazolyl nitrogen; ii) the *cis* or *trans* configuration adopted by the nitroso group with respect to the alkyl chain bound to the pyrazolic nitrogen and perpendicularly folded to the molecular plane.

To verify this hypothesis, we synthesized compounds in which the isox-azole was substituted by a pyrazole moiety, leading to the new isomeric series I and II (Figure 1). The title compounds tested *in vitro* for antifungal activity against *C. Neoformans* and *C. Krusei*, displayed an interesting antifungal activity, in particular compound Ib was 2 and 32 fold more potent than Amphotericin B and Fluconazole, respectively, against *C. krusei*, fungus with intrinsic resistance to many of antifungal azoles.

These results suggest that, depending on the heterocyclic molecule bound to the 5 position of 1*H*-1-R-4-nitrosopyrazoles, it is possible to modulate the antifungal activity of 4- nitrosopyrazoles. *In vitro* metabolism studies and *in vivo* assay are in progress for all described compounds.

Correspondence: Stefania Aiello, Physiology and Pharmacology Unit, Department of Legal, Social and Sports Sciences, University of Palermo, via Caduti senza Croce 3, 90127 Palermo, Italy. E-mail: stefania.aiello@unipa.it

©Copyright S. Aiello et al., 2015 Licensee PAGEPress, Italy Journal of Biological Research 2015; 88:5161

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 3.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.



R':CH₂CH₂CH₃; R: a=H, b=CH₃; c=CH₂CH₃

Figure 1. Isomeric series I and II.

References

- Aiello E, Aiello S, Mingoia F, et al. Synthesis and antimicrobial activity of new 3-(1-R-3- methyl-4-nitroso-1H-5-pyrazolyl)-5methylisoxazole derivatives. Bioorg Med Chem 2000;8:2719-28.
- Aiello S, Aiello E, Orioli M, Carini M. 3-(1-R-3-methyl-4-nitroso-1H-5-pyrazolyl)-5-methylisoxazoles: a new class of antifungal compounds. *In vitro* metabolism by rat liver:LC and LC-MS studies. Convegno Nazionale SCI, Sorrento 18-22 Settembre 2002.